Clinical bottom line
Relapsed or refractory chronic lymphocytic leukemia (CLL) remains a therapeutic challenge due to clonal evolution driving resistance to standard treatments. Recent advances in novel agents targeting clonal dynamics, including next-generation BCL-2 inhibitors and non-covalent BTK inhibitors, show promise in overcoming resistance mechanisms. Emerging data suggest these agents may improve progression-free survival (PFS) and provide options for patients with high-risk clonal profiles. However, clinical experience is still evolving, and careful patient selection and monitoring for resistance patterns are essential.
What the evidence shows
Clonal evolution in relapsed/refractory CLL is a key driver of treatment failure and disease progression. Zapatka et al. (2019) demonstrated that while clonal evolution is limited in relapsed cases, it accelerates in refractory disease, underscoring the need for therapies that address evolving resistant clones. Venetoclax, a BCL-2 inhibitor, has been a cornerstone in relapsed/refractory CLL, but early clonal dynamics during treatment can predict resistance emergence (Case Medical Research, 2019). This highlights the importance of understanding clonal shifts to optimize therapy.
Newer agents are emerging to target these resistant clones more effectively. Lisaftoclax, a next-generation BCL-2 inhibitor, has shown promising activity in relapsed/refractory CLL/SLL with a potentially improved safety profile and efficacy in patients with prior venetoclax exposure (DengYue et al., 2025). Additionally, pirtobrutinib, a highly selective non-covalent BTK inhibitor, demonstrated a significant PFS benefit in the BRUIN CLL-313 trial for patients with relapsed/refractory CLL or small lymphocytic lymphoma, including those with prior BTK inhibitor resistance (BRUIN CLL-313, 2025).
These novel agents target distinct mechanisms of clonal survival and resistance, offering therapeutic avenues beyond covalent BTK inhibitors and first-generation BCL-2 inhibitors. Robak et al. (2019) provide a comprehensive overview of treatment options in relapsed/refractory CLL, emphasizing the evolving landscape with these novel targeted therapies.
Caveats and uncertainty
Despite encouraging results, the evidence base for these novel agents remains limited by relatively short follow-up durations and heterogeneous patient populations. The long-term durability of responses and impact on overall survival are not yet fully established. Resistance mechanisms to newer agents like pirtobrutinib and lisaftoclax require further elucidation, as clonal evolution may continue to drive relapse.
Most studies to date have been conducted in heavily pretreated populations, which may limit generalizability to earlier lines of therapy. Additionally, the optimal sequencing or combination of these novel agents with existing therapies is not well defined. Toxicity profiles, especially in frail or elderly patients, warrant careful consideration.
Biomarkers predictive of response and resistance remain under investigation, and routine clinical assays to monitor clonal evolution are not yet standardized. As such, clinical decision-making should integrate molecular profiling where available but remain individualized.
How this may change practice
The introduction of novel agents targeting clonal evolution in relapsed/refractory CLL is poised to expand therapeutic options and improve outcomes for patients with resistant disease. Clinicians should consider these agents, such as lisaftoclax and pirtobrutinib, particularly in patients with prior exposure to venetoclax or covalent BTK inhibitors who demonstrate disease progression.
Incorporating molecular monitoring of clonal dynamics may become increasingly important to guide therapy selection and anticipate resistance. These advances may shift treatment paradigms toward more personalized approaches based on clonal architecture and resistance profiles.
Ongoing clinical trials and real-world evidence will be critical to define optimal sequencing, combination strategies, and patient selection criteria. Until then, multidisciplinary discussion and shared decision-making remain essential in managing relapsed/refractory CLL.